No Detail Found!

Comparison of benefit between dabigatran and warfarin among patients with atrial fibrillation: A systematic review

Author(s)
Amal K. Sulieman Department of Pharmaceutical Practice, College of Pharmacy, Princess Nora bint Abdul Rahman University,Riyadh 11671,Saudi Arabia
Abstract
Warfarin is recognized as the standard antithrombotic agent for stroke prevention. However, new oral anticoagulant such as dabigatran constitutes huge improvement to compensate for the limitation of warfarin. A literature review was performed to compare and contrast the overall benefit of dabigatran and warfarin among patients with atrial fibrillation. We utilized HighWire as the data source for randomized controlled trials based on inclusion and exclusion criteria (from January 2007 to September 2013). Descriptive and quantitative information related to stroke and major bleeding were extracted from each trial. After a comprehensive screening of 298 search results, 17 studies which enrolled a total of 127,594 patients were included. Warfarin was found to have higher mean event rates for incidence of stroke, major bleeding, and net clinical benefit compared to dabigatran 110 mg and dabigatran 150 mg. Dabigatran 110 mg has higher rate of stroke and net clinical benefit than dabigatran 150 mg with less major hemorrhage. Overall, dabigatran had higher efficacy and safety profile than warfarin. Further research is required to determine the clinical feasibility of dabigatran in real-life practice.
Publication Details
Page(s) 33-42
Published Journal: Archives of Pharmacy Practice, Volume: 7, Issue: 2, Year: 2016

Request the full text from PASTIC

Keywords
Stroke, prevention, Warfarin, Dabigatran, atrial fibrillation
References
Wann LS,Lee R,Santangeli P,Natale A.,Managing Atrial Fibrillation Insights Into Pathophysiology A. . .. [Last cited on 2013 Aug, 14 : .
Society HR. Heart,Diseases HR. Heart . .. [Last cited on 2013 Aug, 14 : .
Fuster V,Rydén LE,Cannom DS,Crijns HJ,Curtis AB,Ellenbogen KA .2011 .Management of patients with atrial fibrillation;. [Last cited on 2013 Aug, 14 : .
Hart RG,Pearce L A,Aguilar MI .2007 .Meta‑analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 146 : 857-67.
Strobeck JE .2012 .Stroke prevention in atrial fibrillation: Managing the risks in light of new oral anticoagulants. Cardiovasc Drugs Ther, 26 : 331-8.
Providência R,Albenque JP,Combes S,Bouzeman A,Casteigt B,Combes N .2014 .Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: A systematic review and meta‑analysis. Heart, 100 : 324-35.
Sacco RL,Kasner SE,Broderick JP,Caplan LR,Connors JJ,Culebras A .2013 .An updated definition of stroke for the 21st century: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 44 : 2064-89.
Ezekowitz MD,Reilly PA,Nehmiz G,Simmers TA,Nagarakanti R,Parcham‑Azad K .2007 .Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol, 100 : 14192-6.
Connolly SJ,Ezekowitz MD,Yusuf S,Eikelboom J,Oldgren J,Parekh A .2009 .Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 361 : 1139-51.
Ezekowitz MD,Wallentin L,Connolly SJ,Parekh A,Chernick MR,Pogue J .2010 .Dabigatran and warfarin in Vitamin K antagonist‑naive and ‑experienced cohorts with atrial fibrillation. Circulation, 122 : 2246-53.
Diener HC,Connolly SJ,Ezekowitz MD,Wallentin L,Reilly PA,Yang S .2010 .Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE‑LY trial. Lancet Neurol, 9 : 1157-63.
Hori M,Connolly SJ,Ezekowitz MD,Reilly PA,Yusuf S,Wallentin L,RE‑LY Investigators L .2011 .Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation - Suba‑nalysis in Japanese population in REL‑Y trial. Circ J, 75 : 800-5.
Pink J,Lane S,Pirmohamed M,Hughes DA .2011 .Dabigatran etexilate versus warfarin in management of nonv‑alvular atrial fibrillation in UK context: Quantitative benefith‑arm and economic analyses. BMJ, 343 : d6333.
Eikelboom JW,Wallentin L,Connolly SJ,Ezekowitz M,Healey JS,Oldgren J .2011 .Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long‑term anticoagulant therapy (RE‑LY) trial. Circulation, 123 : 2363-72.
Nagarakanti R,Ezekowitz MD,Oldgren J,Yang S,Chernick M,Aikens TH .2011 .Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion. Circulation, 123 : 131-6.
Hart RG,Diener HC,Yang S,Connolly SJ,Wallentin L,Reilly PA .2012 .Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE‑LY trial. Stroke, 43 : 1511-7.
Guo Y,Pisters R,Apostolakis S,Blann AD,Wang H,Zhao X .2013 .Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: Would the novel oral anticoagulants have an impact?. Int J Cardiol, 168 : 515-22.
Schneeweiss S,Gagne JJ,Patrick AR,Choudhry NK,Avorn J .2012 .Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes, 5 : 480-6.
Healey JS,Eikelboom J,Yang S,Themeles E,Connolly SJ,Yusuf S .2013 .Response to letters regarding article, Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the randomized evaluation of longt‑erm anticoagulation therapy (REL‑Y) randomized trial. Circulation, 127 : e506.
Eikelboom J,Connolly SJ,Hart RG,Wallentin L,Reilly P,Oldgren J .2012 .Balancing the Benefits and risks of two doses of dabigatran compared with warfarin in atrial fibrillation. Circulation, 126 : A14433.
Hori M,Connolly SJ,Zhu J,Liu LS,Lau CP,Pais P .2013 .Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and nonA‑sians with atrial fibrillation. Stroke, 44 : 18916.
Flaker G,Ezekowitz M,Yusuf S,Wallentin L,Noack H,Brueckmann M .2012 .Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: Results from the RE‑LY (Randomized Evaluation of LongT‑erm Anticoagulation Therapy) study. J Am Coll Cardiol, 59 : 854-5.
Lip GY,Rasmussen LH,Olsson SB,Jensen EC,Persson AL,Eriksson U .2009 .Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation: A randomized dose‑guiding, safety, and tolerability study of four doses of AZD0837 vs. Vitamin K antagonists. Eur Heart J, 30 : 2897-907.
Oldgren J,Ezekowitz MD,Alings M,Diener HC,Reilly PA,Yusuf S .2011 .Dabigatran versus warfarin and impact of CHAD2V‑ASC score on outcome in atrial fibrillation patients: A RE‑LY subgroup analysis. J Am Coll Cardiol, 14 : E7.
Site HG .2006 .Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): A randomised controlled trial. Lancet, 367 : 1903-12.
Mackman N. .2009 .The role of tissue factor and factor VIIa in hemostasis. Anesth Analg, 108 : 1447-52.
Steffel J,Lüscher TF,Tanner FC .2006 .Tissue factor in cardiovascular diseases: Molecular mechanisms and clinical implications. Circulation, 113 : 722-31.
Hirsh J,Dalen J,Anderson DR,Poller L,Bussey H,Ansell J .2001 .Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 119 1 Suppl: : 8S-21S.
0

Citations

0

Downloads

12

Views